Cargando…

Structural basis of main proteases of HCoV-229E bound to inhibitor PF-07304814 and PF-07321332

PF-07321332 and PF-07304814, inhibitors against SARS-CoV-2 developed by Pfizer, exhibit broad-spectrum inhibitory activity against the main protease (M(pro)) from various coronaviruses. Structures of PF-07321332 or PF-07304814 in complex with M(pro)s of various coronaviruses reveal their inhibitory...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Yanru, Wang, Weiwei, Zeng, Pei, Feng, Jingwen, Li, Dongyang, Jing, Yue, Zhang, Jin, Yin, Xiushan, Li, Jian, Ye, Heyang, Wang, Qisheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020134/ https://www.ncbi.nlm.nih.gov/pubmed/36965419 http://dx.doi.org/10.1016/j.bbrc.2023.03.043

Ejemplares similares

Structural Basis of Main Proteases of Coronavirus Bound to Drug Candidate PF-07304814
por: Li, Jian, et al.
Publicado: (2022)

Structural Basis of the Main Proteases of Coronavirus Bound to Drug Candidate PF-07321332
por: Li, Jian, et al.
Publicado: (2022)

Crystal structures of main protease (M(pro)) mutants of SARS-CoV-2 variants bound to PF-07304814
por: Jiang, Haihai, et al.
Publicado: (2023)

Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332
por: Zhao, Yao, et al.
Publicado: (2021)

Characterization of the non-covalent interaction between the PF-07321332 inhibitor and the SARS-CoV-2 main protease
por: Macchiagodena, Marina, et al.
Publicado: (2022)

Total synthesis of antiviral drug, nirmatrelvir (PF-07321332)
por: Shekhar, Chandra, et al.
Publicado: (2022)

Adaptation of the endemic coronaviruses HCoV-OC43 and HCoV-229E to the human host
por: Forni, Diego, et al.
Publicado: (2021)

HCoV-229E Infects and Activates Monocytes
por: Desforges, Marc, et al.
Publicado: (2006)

Titration of Human Coronaviruses, HCoV-229E and HCoV-OC43, by an Indirect Immunoperoxidase Assay
por: Lambert, Francine, et al.
Publicado: (2007)

Heparan Sulfate and Enoxaparin Interact at the Interface of the Spike Protein of HCoV-229E but Not with HCoV-OC43
por: Fuochi, Virginia, et al.
Publicado: (2023)

Structural characterization of the HCoV-229E fusion core
por: Zhang, Wei, et al.
Publicado: (2018)

Supervised Molecular Dynamics (SuMD) Insights into the mechanism of action of SARS-CoV-2 main protease inhibitor PF-07321332
por: Pavan, Matteo, et al.
Publicado: (2021)

Seasonality and immunity to laboratory-confirmed seasonal coronaviruses (HCoV-NL63, HCoV-OC43, and HCoV-229E): results from the Flu Watch cohort study
por: Aldridge, Robert W., et al.
Publicado: (2020)

Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 management
por: Heskin, Joseph, et al.
Publicado: (2022)

Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506
por: Carbajo-Lozoya, Javier, et al.
Publicado: (2012)

The human coronavirus HCoV-229E S-protein structure and receptor binding
por: Li, Zhijie, et al.
Publicado: (2019)

The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations
por: Joyce, Ryan P., et al.
Publicado: (2022)

Mouse models susceptible to HCoV-229E and HCoV-NL63 and cross protection from challenge with SARS-CoV-2
por: Liu, Donglan, et al.
Publicado: (2023)

The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern
por: Abdelnabi, Rana, et al.
Publicado: (2022)

Fatal human coronavirus 229E (HCoV-229E) and RSV–Related pneumonia in an AIDS patient from Colombia
por: Villamil-Gómez, Wilmer E., et al.
Publicado: (2020)

Review of preclinical data of PF-07304814 and its active metabolite derivatives against SARS-CoV-2 infection
por: Chen, Wujun, et al.
Publicado: (2022)

Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Intravenous Infusions of PF-07304814 (Lufotrelvir) in Participants Hospitalized With COVID-19
por: Robinson, Philip, et al.
Publicado: (2023)

Insights into the binding and covalent inhibition mechanism of PF-07321332 to SARS-CoV-2 M(pro)
por: Ngo, Son Tung, et al.
Publicado: (2022)

Pan-Coronavirus CRISPR-CasRx Effector System Significantly Reduces Viable Titer in HCoV-OC43, HCoV-229E, and SARS-CoV-2
por: Mayes, Cathryn M., et al.
Publicado: (2023)

Exploring the Binding Mechanism of PF-07321332 SARS-CoV-2 Protease Inhibitor through Molecular Dynamics and Binding Free Energy Simulations
por: Ahmad, Bilal, et al.
Publicado: (2021)

Comparative Antiviral Activity of Remdesivir and Anti-HIV Nucleoside Analogs against Human Coronavirus 229E (HCoV-229E)
por: Parang, Keykavous, et al.
Publicado: (2020)

Characterization of HCoV-229E fusion core: Implications for structure basis of coronavirus membrane fusion
por: Liu, Cheng, et al.
Publicado: (2006)

Resveratrol Inhibits HCoV-229E and SARS-CoV-2 Coronavirus Replication In Vitro
por: Pasquereau, Sébastien, et al.
Publicado: (2021)

Coronavirus humains (HCoV)
por: Vabret, A., et al.
Publicado: (2009)

PF‐07321332 (Nirmatrelvir) does not interact with human ENT1 or ENT2: Implications for COVID‐19 patients
por: Hau, Raymond K., et al.
Publicado: (2022)

Transcriptomic profiling and genomic mutational analysis of Human coronavirus (HCoV)-229E -infected human cells
por: Friedman, Nehemya, et al.
Publicado: (2021)

Cryo-EM analysis of the HCoV-229E spike glycoprotein reveals dynamic prefusion conformational changes
por: Song, Xiyong, et al.
Publicado: (2021)

Interaction of the new inhibitor paxlovid (PF-07321332) and ivermectin with the monomer of the main protease SARS-CoV-2: A volumetric study based on molecular dynamics, elastic networks, classical thermodynamics and SPT
por: Alvarado, Ysaias José, et al.
Publicado: (2022)

The therapeutic promises of Lianhuaqingke in the mice model of coronavirus pneumonia (HCoV-229E and SARS-CoV-2)
por: Wang, Mingye, et al.
Publicado: (2021)

Antiviral Activity of Ficus rubiginosa Leaf Extracts against HSV-1, HCoV-229E and PV-1
por: Dell’Annunziata, Federica, et al.
Publicado: (2022)

Ferulic acid derivatives block coronaviruses HCoV-229E and SARS-CoV-2 replication in vitro
por: Pasquereau, Sébastien, et al.
Publicado: (2022)

Corrigendum to ’Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506’ Virus Research (2012) 165/1 [112-117]: Corrigendum
por: Carbajo-Lozoya, Javier, et al.
Publicado: (2022)

Reproductive and developmental safety of nirmatrelvir (PF-07321332), an oral SARS-CoV-2 M(pro) inhibitor in animal models
por: Catlin, N.R., et al.
Publicado: (2022)

Liposomal Lactoferrin Exerts Antiviral Activity against HCoV-229E and SARS-CoV-2 Pseudoviruses In Vitro
por: Andreu, Sabina, et al.
Publicado: (2023)

Previous viral symptoms and individual mothers influenced the leveled duration of human milk antibodies cross-reactive to S1 and S2 subunits from SARS-CoV-2, HCoV-229E, and HCoV-OC43
por: Demers-Mathieu, Veronique, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9s941cu2jfu41cmp76b3dhc31j